Physician profile
Ana L Paredes
NPI 1922055615
$1,293.68
in general payments reported to CMS, 2019-2025
18 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $104 · 2022: $268 · 2023: $125 · 2024: $246 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $365.27 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $304.15 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $104.36 | 2019 | |
| Kyowa Kirin, INC. | $82.07 | 2023-2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $65.08 | 2024 | Purified Cortrophin Gel, Valsartan |
| Alnylam Pharmaceuticals INC. | $54.77 | 2024-2025 | Oxlumo, Givlaari |
| Travere Therapeutics, INC. | $52.23 | 2022-2024 | |
| Mozarc Medical US LLC | $33.08 | 2025 | Carpediem |
| Calliditas Therapeutics US INC. | $27.16 | 2025 | Tarpeyo |
| Ipsen Biopharmaceuticals, INC | $26.73 | 2025 | Bylvay |
| Apellis Pharmaceuticals, INC. | $20.42 | 2025 | |
| Baxter Healthcare | $19.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Paredes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.